- Home
- About
- Team
- Portfolio
- 4energy Limited
- Abzena plc
- Accutronics Limited
- Acea Health: Flynotes
- Apex Molecular
- Arlabion
- Atlantic Link Limited
- Biofortuna Limited
- Biohabit
- Biorelate
- Bitrobius Genetics
- Blackstar Amplification Limited
- Blueberry Therapeutics
- Brainberry (formerly Cerebrum Matter)
- Bsolve Dental Limited
- BWB Consulting Limited
- CanCertain
- Clin-e-Cal
- CroBio
- Crystallon Limited
- Cyclops Limited
- Cytox
- De-Pack Limited
- Food and Drug Analytical Services Limited
- Gendius
- Haemostatix
- Hangar Seven Limited
- Healum
- INFEX Therapeutics
- Kick Sport Limited
- Lifeskills Education Holdings Limited
- Lumora Limited
- Manchester Biotech (Manchester Biogel)
- Manchester Imaging
- Maxwellia
- metaLinear
- MicroBioSensor
- Monica Healthcare Limited
- Monument Therapeutics
- MyHelp
- Nexus Labs
- Oracle Care Limited
- OVO Biomanufacturing
- Oxford Biotherapeutics Limited
- Panthera Biopartners
- Pebble Biotechnology Laboratories
- Pencil Biosciences
- Pill Connect
- Pronec
- Proveca
- QV Bioelectronics
- R2C Online Limited
- R5 Pharmaceuticals Limited
- Renephra
- Rinicare
- Sight and Sound Limited
- Silver Lining Solutions Limited
- SwabTech
- Systems Integration (Trading) Limited
- Tectores
- Trio Healthcare
- Turbine Efficiency Limited
- Virustatic
- Viscgo
- Whelan Refining Limited
- Yospace Limited
- YourMedPack
- Funds
- News
- Maxwellia launches unexpected menstrual health campaign following concerning survey results
- Monument Therapeutics launches first clinical study of MT1988, a novel treatment for cognitive impairment associated with schizophrenia
- Monument Therapeutics announces appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to guide schizophrenia program
- Apex Molecular Ltd appoints Dr Jason Tierney as a Medicinal Chemistry Consultant
- Monument Therapeutics secures £1m investment to fund its schizophrenia programme and drive next stage of growth
- LYVA Labs invests £50,000 into health innovators Tectores
- Monument Therapeutics announces grant of UK patent for neuroinflammation compound MT1980
- First NCFB patient dosed in RESP-X Phase IIa study
- QV Bioelectronics delivers breakthrough pre-clinical safety and efficacy results for Electric Field Therapy in the treatment of Glioblastoma
- Respected pharma data science pioneer Dr Ben Sidders to spearhead Biorelate's next growth phase as Chief Scientific Officer
- QV Bioelectronics secures £343,000 from Innovate UK’s Cancer Therapeutics programme to develop a new treatment for childhood brain tumours
- Infex Therapeutics to present RESP-X Phase I data at ERS Congress
- Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001
- Oxford BioTherapeutics named 'Best Tech SME of the Year' at Thames Valley Tech & Innovation Awards 2024
- Wirral footcare manufacturer Tectores steps into India
- Infex Therapeutics strengthens its senior leadership team
- Biofortuna completes acquisition of biological sample storage experts Cryoniss
- CroBio announces completion of $1.55 million seed round
- Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development
- Maxwellia revolutionises menstrual health category in pharmacy with the introduction of Evana® and Ultravana®
- Sight and Sound announces partnership with Speaksee
- Oxford BioTherapeutics announces launch of enhanced discovery platform, OGAP®-Verify, at World ADC Conference 2024
- Pill Connect announces its acceptance onto the leading CDMO’s smart packaging supply program
- Maxwellia announces the launch of LoviTest™
- LoviOne® crowned winner of the Pharmacy Product of the Year - Consumers’ Choice 2024
- Innovation funding boost for blister prevention firm
- Oxford BioTherapeutics announces first patient dosed with lead candidate, OBT076, in Phase 1b trial in adenoid cystic carcinomas of the head and neck
- Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
- Oxford BioTherapeutics announces partner Boehringer Ingelheim received U.S. FDA Fast Track Designation for BI 764532 for potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of the lung
- Blueberry Therapeutics meets primary and secondary endpoints in Phase 2b trial in onychomycosis
- Infex Therapeutics - RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
- Oxford BioTherapeutics announces partner Boehringer Ingelheim dosed first patient in Phase 2 trial with BI 764532 in small cell lung cancer and other neuroendocrine cancers
- QV Bioelectronics and Incubate Bio announce successful outcome of strategic collaboration to accelerate new treatment option for Glioblastoma
- Oxford BioTherapeutics relocates UK Headquarters to strategic and cutting-edge R&D location at The Oxford Science Park
- US FDA Fast Track designation granted to BI 764532 for the treatment of extensive stage small cell lung cancer
- Pencil Biosciences completes fundraise to develop novel gene editing and modulation technology
- Report shows YOURmeds medication management system helped councils generate significant cost savings
- Maxwellia launches new brand of emergency contraception
- Gendius receives UKCA mark for CKD Screen Prioritizer
- Infex receives approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
- Infex Therapeutics - Clinical candidate nominated for COV-X programme
- Oxford BioTherapeutics initiates Phase Ib clinical trial for OBT076 in patients with advanced solid tumours
- CPI Enterprises to help fund innovative medical device for brain tumours
- AI influencer tackles TikTok health trend
- Cytox brings ground-breaking genetic risk test for Alzheimer's disease to the UK
- Oxford BioTherapeutics and Boehringer Ingelheim agree on extension to second multi-year collaboration in cancer immunology
- Study by Healum demonstrates its platform improves health outcomes for diabetes patients
- Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC
- INFEX Therapeutics interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
- QV Bioelectronics Awarded £860,000 Innovate UK Boost
- Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation
- Oxford BioTherapeutics to announce new fully integrated ADC Engine at World ADC Conference 2023
- Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award
- INFEX Therapeutics strengthens Board with appointment of Professor Colm Leonard as a Non-Executive Director
- Healum wins NHS contract for patients at risk of CVD
- QV Bioelectronics raises £2m to develop revolutionary electric field therapy implant for brain tumour treatment
- Monument Therapeutics announces first clinical study of MT1980 successfully meets all objectives
- Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
- Diabetes self-management app intellin® is a cost-effective solution for preventing diabetic foot ulcer recurrence
- Pill Connect dispenser supports clinical trial for personalised Tuberculosis care
- Extra £6.5m secured by tech firm which uses AI to speed up scientific discovery as it eyes US expansion
- Blueberry Therapeutics Ltd announces nomination of BB1511 for clinical development for the treatment of Atopic Dermatitis (Eczema)
- Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
- Biorelate and Copyright Clearance Centre announce strategic integration
- First Choice Neurology partners with Cytox
- Oxford BioTherapeutics enters into Commercial License Agreement with Genmab
- “Gift of time” could enable nearly 100 more kidney transplants each year
- Breakthrough in identifying risk of renal impairment in people with diabetes
- INFEX Therapeutics awarded Biomedical Catalyst grant for COV-X project
- Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme
- MicroBioSensor launches QUICKCHECK™ designed in partnership with Smallfry
- iiCON to expand pipeline following Research England funding boost
- Monument Therapeutics announces the start of its first clinical study for novel treatment for neuroinflammation
- Oxford BioTherapeutics announces research collaboration with ImmunoGen to develop novel Antibody-Drug Conjugates
- Proveca enters an exclusive agreement with Mawdsley Brooks Brazil
- Rinicare’s SAFE falls reduction technology granted new UK patent
- Trial to assess Acute Kidney Injury risk prediction technology starts at MFT
- Oxford BioTherapeutics to present initial positive data from Phase I trial at ASCO 2022
- NIHR backed AI care planning network goes live
- Oxford BioTherapeutics announces collaboration with Agenus
- CARB-X receives additional $370m from U.S. Government and Wellcome
- Blueberry Therapeutics provides regulatory update on Phase 2b trial
- Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme
- Maxwellia appoints Ian Adamson as Strategic Advisor
- Catapult Ventures records 3.3x return from exit of Panthera Biopartners
- Medicine switching expert Maxwellia continues to drive shift to self-care with two more pharmacy products in the launch pipeline
- Oxford BioTherapeutics grants third exclusive license to Boehringer Ingelheim
- OBT to present preliminary clinical data from ongoing Expansion Phase I Trial
- Proveca announces agreement with Biopas Laboratories
- Cell Guidance Systems and Manchester BIOGEL Collaborate to Launch PODS-PeptiGels for 3D Cell Culture
- Pill Connect releases adherence data to demonstrate efficacy of smart dosing technology
- Blueberry Therapeutics provides R&D update and reports progress across dermatology portfolio
- You & Type 2 diabetes project helps transform patient experiences supported by Healum technology
- Panthera wins contract to recruit patients for Roche breast cancer study
- Trio Healthcare liberates patients with new breathable silicone bag
- Stratified medicine company Monument Therapeutics announces two new developments
- NICE releases Medtech Innovation Briefing for YOURmeds smart medication management system
- Proveca announces new partnership with ExCEEd Orphan
- Gendius initiates GP data study to develop enhanced risk prediction tools for diabetes
- QV Bioelectronics Awarded £630,000 Under Innovate UK Biomedical Catalyst Award
- Two new senior appointments at Manchester Imaging
- Alder Hey children’s hospital and Proveca announce collaboration
- Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
- INFEX Therapeutics agrees partnership with Colibri Scientific to provide services for RESP-X program
- Panthera Biopartners leads the way in the UK with specialist research sites for NASH and NAFLD studies
- INFEX Therapeutics scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
- Proveca sponsored clinical trial starts in France to evaluate the impact of its drug Sialanar®
- Manchester Biogel and Resnova to sign a strategic agreement for the distribution in Italy of innovative solutions for 3D Cell Culture
- Rinicare enters data sharing collaboration with Manchester University NHS Foundation Trust to further develop clinical risk prediction technology
- Trio Healthcare takes leap forward in international growth strategy by opening first office in US
- Biofortuna relocates to purpose built facilities and more than doubles its capacity
- Panthera@theRutherford partnership commences first UK multicentre oncology trial in prostate cancer
- ADEPT study proves value of dental AI using AssistDent® AI software
- Rinicare confirms first European evaluation of its AI falls prevention technology
- Channel 4 Ventures invests in Maxwellia to support the launch of Lovima®
- Maxwellia announces appointment of Sara Al-Attbi as Medical Affairs Pharmacist
- Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease
- New study launched to investigate targeted treatments for Schizophrenia
- Boehringer Ingelheim and Oxford BioTherapeutics partnership advances second oncology drug candidate into the clinic
- Maxwellia strengthens its Marketing team with two new appointments
- Rinicare’s continuous vital signs monitoring technology deployed across hospitals and Covid-19 health centres in India
- £2m funding boost for Infex’s work on pandemic preparedness
- Rinicare launches new AI-driven risk prediction solution for atrial fibrillation
- Viscgo completes £315k investment round
- Clin-e-Cal wins share of £4m tech fund to revolutionise asthma self-management
- Panthera steps up its move into oncology trials with more than 12 trials in the pipeline and a prostate trial underway
- Gendius to collaborate with The University of Manchester on new Human-AI research teams
- Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
- Cytox strengthens team to support commercialisation of genoSCORE test to predict risk of cognitive decline due to Alzheimer’s disease
- Women can buy Maxwellia’s Lovima® contraceptive pill from pharmacies for first time in UK history
- QV Bioelectronics raises £735k for development of implanted electric field therapy device for brain cancer treatment
- Gendius - new partnership will help diabetics to manage their conditions
- Cambridge Cognition completes spin-out of Monument Therapeutics
- Infinity BiologiX and Cytox collaborate to provide new genetic test to predict the risk of cognitive decline due to Alzheimer’s Disease
- Rinicare to provide continuous vital signs monitoring technology to Indian healthcare system
- Innovate UK funds AssistDent adaption for university dental schools
- Blueberry Therapeutics secures further investment
- Infex Therapeutics partners with Alderley Analytical
- INFEX Therapeutics appoints Lonza to manufacture new lung infection drug
- Digital health start-up Clin-e-cal launches free app to help improve inhaler technique and reduce asthma attacks
- British Pharmaceutical Company Maxwellia Secures Government Future Fund investment to Spearhead Shift in Self-Care
- Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study
- Viscgo secures investment to launch its innovative device to improve quality of life for people with swallowing difficulties
- Maxwellia on course to launch self-care alternatives following £3.2m funding round
- Deals agreed as Infex's resistance bypass drug program heads for clinic
- Panthera Biopartners appoints corporate financier Christopher Steed as a non-executive director to continue UK and overseas expansion
- Infex focuses on pandemic preparedness with Covid patent
- Healum closes investment round to develop UKRI funded AI powered patient management system for people with long term conditions
- Panthera Biopartners commences a Ph 3 trial for AstraZeneca’s monoclonal antibody combination to reduce the effects of COVID-19
- UK healthtech startup Rinicare appoints leading AI and machine learning specialist as Chief Technology and Data Officer
- Panthera further strengthens its oncology clinical trials team with the appointment of Matt Cooper as General Manager Oncology
- Biorelate signs multi-year deal with e-therapeutics
- Cytox launches genoSCORE-LAB test to predict the risk of developing Alzheimer’s disease
- The pill could be sold in pharmacies without prescription
- Maxwellia spearheading shift to self-care with three pharmacy products in launch pipeline
- Maxwellia announces appointment of Tim Holmes as Head of Sales
- AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence
- Blueberry Therapeutics announces extension of its Series B round with investment from Medical Incubator Japan and US Dermatology Syndicate
- Chris Hall elected chairman of Pill Connect
- Panthera continues to sign up new clinical trials across its UK network of dedicated clinical trial sites
- Manchester Imaging teams up with Michelson Diagnostics
- Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform
- Maxwellia Announces Appointment of Jack Grimshaw as Finance Director
- Funding package announced for blister prevention firm Pellitec
- Kite and Oxford Biotherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours
- Panthera assists in AstraZeneca’s phase III trial of antibody combination for prevention of Covid-19
- British MedTech Rinicare poised to respond to the challenges of the new healthcare environment
- Pill Connect expands its team with the appointment of Richard Hall as Director of Quality
- Catapult Ventures invests in OVO Biomanufacturing to improve the manufacturing efficiency of viral vaccines and gene therapies
- Exciting new collaboration to develop fully synthetic animal-free scaffolds
- Maven Equity Finance NPIF invests alongside Catapult in digital healthcare consent platform Flynotes
- Maxwellia looking into daily contraceptive Rx-To-OTC switch
- Digi.me partners with Gendius to allow users to connect their health records to its smart diabetes management platform
- Cytox publishes research showing genoSCORE-LAB test can predict risk of cognitive decline due to Alzheimer’s without invasive procedures
- The Medication Adherence Expertise Center and Pill Connect’s smart adherence system help patients with TB take their medication regularly
- Infex Therapeutics and LifeArc announce collaboration to defeat superbugs
- Biorelate - AI-based drug discovery tool free access extended
- Biotech investor backs electronic smart pill bottle - Pill Connect
- North West entrepreneurs secure inclusion on international wellbeing accelerator programme
- Cytox appoints Yourgene Genomic Services as European partner
- Medicine adherence and compliance innovation YOURmeds wins SEAS2GROW award in AgeTech accelerator programme
- Face mask firm Virustatic expands and signs international distribution deals
- Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration
- Crowdcube success for Clin-e-cal
- Intellin wins at Health Tech Digital Awards
- Flynotes: Dental Fallow Time Calculator to be launched
- Study shows Clement Clarke’s Clip-Tone device improves inhaler technique
- Catapult Ventures announces investment in Panthera Biopartners
- Covid-19 Pandemic Spurs Adoption and Investment in Digital Health Technologies
- Cytox signs licence agreement with Cardiff University for polygenic risk score technology key to development of lead product genoSCORE(TM)
- Clin-e-Cal launches Crowdcube campaign
- Catapult Ventures announces investment in digital health start-up MyHelp
- Catapult Ventures invests in agricultural synthetic biology start-up CroBio
- Catapult announces the sale of Oracle Care & Education
- YourMedPack announces growth funding from Catapult Ventures for smart medication packs
- Gendius awarded a share of £200,000 through Health Innovation Manchester Momentum Fund
- Major boost in global fight against antimicrobial resistance as AMR Centre receives share of Strength in Places Fund award
- Gendius partners with AstraZeneca to develop diabetes management support for patients in the Gulf region
- Elucid Digital Health and Clin-e-Cal feature in the Business Cloud 100 HealthTech Pioneers List
- Gendius announces launch of CrowdCube campaign for Intellin® diabetes management app
- Biorelate offers free access to AI-based drug discovery tool: Galactic
- Collaboration between Clin-e-Cal and Clement Clarke International aims to make inhalers smarter
- Elucid Digital Health reduces smart Pill Connect bottle to a smart cap dispenser
- Medtech start-up Gendius appoints new Chairman as its smart diabetes management app reaches 100,000 downloads worldwide
- Catapult Ventures appoints Vijay Curthan as Investment Director; promotes Emma Johnson to Associate
- Trials are ramped up for breakthrough medical device from MicroBioSensor
- Intellin diabetes app enhanced to capture COVID-19 data
- Clin-e-Cal Rafi-Tone App listed in the COVID19 Health App Formulary
- OBT achieves further milestone in Boehringer Ingelheim collaboration
- MicroBioSensor - New device for treatment of peritonitis undergoes clinical trials
- The AMR Centre signs agreement with Microbiotix to co-develop treatment for gonorrhoea
- Blueberry Therapeutics announces new Clinical Science Lead
- Cytox MedNous coverage: Genetic risk assessment in Alzheimer's disease
- Rinicare receives funding support from Innovate UK
- Catapult invests in Biohabit through the GM&C Life Sciences Fund
- Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
- Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors
- Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors
- Cytox appoints Ian Gilham as new Chairman of the Board
- UKI2S, Catapult Ventures and Jonathan Milner invest £500k in Gene Modulation Newcomer Pencil Biosciences
- AMRC - Dr Peter Jackson article in Laboratory News
- AMR Centre - World Antibiotic Awareness Week
- AMR Centre candidate targets superbugs with problem metallo-β-lactamase enzymes
- Nexus Labs selected for prestigious Accelerator Programme at Alderley Park
- Maxwellia's Anna Maxwell nominated for Top 50 Movers & Shakers in BioBusiness 2019
- Biorelate launches AI-powered curation engine, Galactic, to combat the growing challenge of information overload in biomedicine.
- Gendius selected for Pitch@Palace 12.0
- Patient feedback suggests that smart pill bottle could help improve adherence to critical medications
- 2019 BioCap Call for Pitches Competition Winner Announced
- Sight and Sound Technology meet with Microsoft CEO
- Could smart pill bottles dispense a solution to drug non-adherence?
- AI-driven growth: ‘Sat nav’ for diabetes Gendius has huge ambitions after £500k fundraise
- eLucid gets US patents for smart pill dispenser device
- UP Ventures and Novartis announce Cohort for Greater Manchester Future of Health Challenge
- Rinicare Announces Appointment Of New Chairman
- Rinicare SAFE: Ground-breaking UHMBT research study has potential to transform care on hospital wards across UK
- The smart pill pot tells you (and your doctor) if you miss a dose
- Dementia testing specialist boosted with six-figure investment
- The AMR Centre set for partnership with Shionogi for new superbug therapy
- University and healthtech firm eLucid mHealth collaborate to develop smart pill dispenser
- Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate
- New Hope for Port Wine Stain Patients from a Novel Image-Guided Treatment
- Clin-e-Cal Rafi-Tone app shows important benefits in Salford study
- Elucid mHealth launches smart pill bottle to monitor patient adherence
- Biorelate appoints Kevin Cox as Chairman to support its rapid expansion plans
- Nexus Labs announces launch of Surgical Teaching
- Catapult exits R2C Online
- The AMR Centre secures £2.3m funding boost
- BioFilm announces new brand - Be
- Rinicare announces PRIME product launch
- UK AI companies Biorelate and Intellegens win share of £20m in Innovate UK grant competition to explore creation of advanced data curation tool
- Nexus Labs welcomes new Senior Clinical Editor
- Yospace sale to RTL to generate an expected 6.7x return for Catapult Ventures
- Apex Molecular Plans Expansion Following Rebrand
- AMR Centre hails government action plan as ‘critical step’ in tackling antibiotic crisis
- Gendius announces launch of Intellin®
- Peter Hamer joins SurgaColl as Chief Executive Officer
- Maxwellia expand their team with two new appointments
- Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics
- Med-Tech companies triumph at the Bionow Awards
- Blueberry Therapeutics Announce Positive Results from a Phase I-II Clinical Trial
- Biofilm seals £2.5m funding injection
- R2C Online wins at 2018 Commercial Motor Awards
- YProtech receives £400k funding boost
- UMI3 Ltd showcases innovations to Catapult Ventures
- Clin-e-cal announces investment from Catapult Ventures to advance its pipeline of innovative digital health respiratory applications
- Yospace Provides IBC Award-Winning Solution For Medialaan
- Cytox expands collaboration with AIBL to identify those most at risk to rapidly progress to Alzheimer’s
- NPIF - Maven Equity Finance and Catapult Ventures, alongside new Manchester Tech Trust angel group, invest £700,000 in Biorelate
- GM&C Life Sciences Fund announces 25th investment
- Yospace, Spotx and Kaltura come together on advanced advertising
- Catapult exits Stagecoach
- CLYZ Labs announces seed funding from Catapult Ventures to develop Cancertain™ test for personalised cancer treatment
- Blueberry Therapeutics Limited closes £10m funding to support development of nanomedicines portfolio
- Nexus Labs announces seed funding from Catapult Ventures and BioCity to launch SurgicalTeaching.com
- Abzena signs protein engineering agreement with NYU Langone Health
- Innovate UK Announces Precision Medicines Innovation Fund
- Abzena and Telix sign strategic manufacturing and bioconjugation agreement
- SurgaColl Partners with Sparta to Deliver High-Quality Tissue Regeneration Products, Improve Accessibility and Time-to-Market
- Acquisition of BWB by CAF Group wins East Midlands Deal of the Year
- Cytox launches collaboration agreement with Mayo Clinic to evaluate novel genetic based approaches for assessing Alzheimer’s risk
- New Early-Warning Device To Detect Infection In Dialysis Patients Completes Successful Clinical Pilot In Manchester
- Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer's Risk to Include Saliva Samples
- Maxwellia announces funding to accelerate its mission for Self Care
- Yospace To Showcase The World’s Most Advanced Server-Side Ad Insertion Technology At NAB Show
- Renephra Secures Investment from Deepbridge Capital and Catapult Ventures
- Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository
- Cytox awarded new Innovate UK funding for Alzheimer’s disease testing
- Oxford BioTherapeutics Appoints Chief Medical Officer, Abderrahim Fandi M.D., Ph.D.
- r2c Online connects over 50,000 fleet and workshop users
- R2C software saves Allan Morris Transport £100,000
- Manchester Imaging Raises £600k to Launch Dental Diagnostic Software
- Australia receives first two revolutionary skin cancer diagnostic machines from VivoSight
- Acea Health announces funding from Catapult Ventures and PUBLIC to launch innovative digital dental and medical consent platform - Flynotes
- Yospace and NexPlayer announce integration
- e-Therapeutics to collaborate with Intellegens and Biorelate to enhance and extend its AI technology capabilities
- SurgaColl Holdings Ltd announces Series A funding, opens HQ in Alderley Park
- Abzena wins $5m-plus deal with US biotech client
- Biofilm appoints new Chief Executive
- Microbiosensor named investment deal of the year at Bionow Awards
- metaLinear Ltd secures £255k seed investment for targeted antibacterial research
- Win for r2c Online at the Commercial Motor Awards 2017
- Catapult Ventures appoints Chris Spencer as Venture Partner
- TV4 and Yospace achieve Swedish first with server-side Dynamic Ad Insertion for live channels
- Sciton announces collaboration with Michelson Diagnostics to develop OCT image-guided laser applications
- Ergomed's PeproStat successfully completes Phase II clinical trial
- Arriva Bus & Coach reduce admin time by 40 hours per week with r2c Online
- Gendius announces funding from Catapult Ventures to launch innovative digital health platform for patients living with diabetes
- Ergomed signs first commercialisation deal for Haemostatix products
- AMR Centre to partner with US biotech company
- Medtech company secures investment
- New Opportunities for Menarini and OBT
- Videology partners with Yospace for addressable TV
- Bitmovin partners with Yospace
- Ergomed completes Phase IIb study recruitment six months ahead of schedule for its innovative coagulant PeproStat
- Venson Signs Contract With R2C Online
- Blueberry to progress Nanomedicine platform to include novel Acne therapy
- Catapult portfolio company, BWB, joins CAF Group
- Abzena and OBI Pharma sign ThioBridge™ licence agreement
- BT Sport extends Yospace Dynamic Ad Insertion deal
- BWB Wins Technology Champion Award
- PeproStat Phase IIb study passes recruitment mid-point ahead of schedule – Top line results brought forward to Q4 2017
- Auto Windscreens Joins r2c’s Digital Platform
- Cytox raises £2.6m led by Catapult Ventures to launch predictive test for Alzheimer’s Disease
- Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director
- Proveca and Tanner Pharma Initiate Global Managed Access Program for Sialanar®
- Bioverativ to acquire True North Therapeutics and the Abzena Inside portfolio product, TNT009
- Proctors Transport see vast savings & 100% compliance since using r2c Online’s digital Driver solution.
- Yospace and MTM launch the linear IP video forum at Connected TV World Summit
- Abzena to pursue $12 million investment program to upgrade and expand its San Diego biomanufacturing operations
- Blueberry Therapeutics commence Phase I-II clinical trial of lead product BB2603
- Catapult portfolio company, Hangar Seven, acquired by The Hut Group
- Proveca raises £4m led by Catapult Ventures to launch children’s drug Sialanar in Europe and accelerate children’s medicines pipeline
- Catapult generates 3.5x return from sale of Monica Healthcare
- Catapult Sells Silver Lining Solutions to US Based Genesys®
- BWB Ranked No 59 in the Sunday Times Best 100 Companies
- Edan Instruments Inc. is the new distributor for Monica AN24 in China
- Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans
- r2c Online gears transport platform for growth
- Abzena Signs New ThioBridge License Agreement
- Whistl posts efficiency benefits with r2c Online
- BWB wins major national award for staff retention strategy
- Expansion and diversification deliver record growth for BWB
- Biofortuna reaches key milestones for ReadyPlex™ blood group genotyping product family
- GM&C Life Sciences Fund Invests in YProTech High Value Chemistry Services
- GM&C Life Sciences Fund Invests in SwabTech
- Catapult Ventures Seed Investments
- GM&C Life Sciences Fund makes further seed investments
- Intamac in software deal with Sprue Aegis
- New Board Member joins Monica
- Catapult Ventures appoints Dr Tony Flinn as Venture Partner
- Faron enters into an agreement with Abzena for the manufacture of Clevegen®
- Monica Healthcare is a winner in the 2016 Premier Inc Innovation Celebrations
- Catapult Ventures appoints Dr David Whitcombe as Venture Partner
- Probe Scientific in top disruptive medical technologies index
- Three weeks: Four trophies: One BWB!
- Catapult Ventures sells Haemostatix to Ergomed
- Yospace wins at Mediatel’s Connected Consumer Awards
- Blueberry Therapeutics raises £3m led by GM&C Life Sciences Fund
- Yospace Wins NewBay Media’s Best of Show Award, Presented by TV Technology
- Catapult exits Food and Drug Analytical Services
- Oxford BioTherapeutics Licenses Nerviano Medical Sciences' Drug-Linker Technology to Develop Novel Antibody Drug Conjugates
- Sky Media to use Yospace’s live ad insertion solution for Sky Go
- Abzena issues business update – strong second half momentum
- GM&C Life Sciences Fund announces first investments
- Michelson Diagnostics’ Dynamic OCT Imaging Technology reveals changes in Skin Blood Vessels in Real-Time
- Abzena announces significant licence deal for ThioBridge
- Catapult secures 9x cash return with sale of Accutronics
- Catapult Ventures appoints Dr Gareth King as Investment Manager
- Abzena announces Antitope Consortium receives €1.9m European grant
- Philips and Monica Healthcare announce collaboration for innovative fetal monitoring solution
- Abzena raises £20m and announces acquisition
- Catapult secures exit from Systems Integration through Management Buy-Out
- Catapult secures 5.2x cash return after successful exit from Oxford Cryosystems through Management Buy-Out
- £45m Life Sciences Fund Launched at Alderley Park
- Catapult Ventures announces the acquisition of Lumora by ERBA Diagnostics Mannheim
- Abzena completes PacificGMP acquisition
- Lumora Sells Heat Elution Technology to Roche
- BWB completes a second acquisition
- Oxford BioTherapeutics receives $10 million capital term loan from Silicon Valley Bank
- Biofortuna launches its new approach to custom IVD manufacture and development services
- Silver Lining Solutions makes senior appointment to lead growth in the Americas
- Innovative BWB light rail project shortlisted in competition
- r2c Online deliver ‘tenfold’ increase in productivity for Bertschi UK
- Haemostatix wins healthcare award at Royal Society of Chemistry's emerging technologies showcase
- Monica Healthcare establishes commercial operations in the USA
- BWB Sweeps the Board at the ACE Awards
- Abzena Says Gilead Advancing Antibody to Further Clinical Trials
- The Dark Side nominated for BVA award
- Michelson Diagnostics launches next generation OCT System – VivoSight Dx
- Two partners enter clinical development with biopharmaceuticals enabled by Abzena's technology
- Mumbai's Sion Hospital takes its first delivery of Monica's AN24 foetal monitoring device
- Lumora Named as ‘Company to Watch in 2015’ by Leading Industry Publisher
- Shortlist Hat Trick for BWB at the ACE Engineering Excellence Awards 2015
- BWB – part of the team delivering one of London’s first housing zones – New Bermondsey
- New VP appointment at Abzena
- Cyclops and Thinkware announce innovative content partnership
- Biofortuna appoints new Chairman
- r2c Online software Aids Compliance for Leeds Commercial Vehicle Hire
- Andy Hill Appointed Chief Executive Officer at Michelson Diagnostics
- Monica Healthcare completes new £2 million Investment round
- Biofortuna Ltd closes a £1.5m funding round
- Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim
- Antitope, INSERM and Baylor Institute to collaborate to produce manufacturing cell lines for two novel vaccines for HIV
- Comply Serve wins at Construction Computing Awards
- OBT and Menarini announce start of first-in-human clinical study to treat acute myeloid leukemia
- Amanda Westwood, CEO of Silver Lining Solutions, gives small business tips in This is Money magazine
- Abzena's CEO Dr John Burt talks to Cambridge Business about the company’s recent floatation on AIM and its unusual business model.
- Brandhouse wins Top Industry Design Award
- Hangar Seven acquires Strategic Video Content Specialists, Media Ark
- Michelson Diagnostics launches new improved version of VivoSight OCT scanner with Micro-Camera to aid skin cancer diagnosis
- New Middle East office for UK rail project assurance firm
- OBT announces second clinical development candidate from its $1bn oncology investment alliance
- Intamac continues growth with appointment of new COO & CTO
- Comply Serve secures further funding
- Britvic appoints Brandhouse on Tango
- Abzena’s subsidiary Antitope and University College London enter into Research & Licence Agreement
- Biofortuna expands freeze dried production service
- Oxford BioTherapeutics Appoints Eugen Leo MD PhD MBA as Head of Clinical Development
- Abzena raises £20 Million in connection with forthcoming admission to AIM
- Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
- New class of coagulant gets go ahead for clinical trial
- PolyTherics and Antitope form Abzena
- Oxford Cryosystems Wins Export Award category at Made in England Awards 2014
- Oxford BioTherapeutics Secures Exclusive Global Rights From Amgen and ImmunoG
- Critical Pharmaceuticals announces US patent allowance
- Monica Healthcare secures N'Tech grant
- Oxford Cryosystems helps push the boundaries of the known universe
- Onwards and upwards for BWB Birmingham
- Sprue Aegis plc (“Sprue”) and Intamac to launch connected safety solution
- Biofortuna receives FDA clearance of its SSPGo™ line of HLA molecular diagnostic freeze-dried kits
- New England Biolabs® announces supply agreement with Lumora
- Prime Minister David Cameron visits portfolio company Oxford Cryosystems
- Michelson Diagnostics targets malignant melanoma using OCT imaging with €2.3M EU funding
- Michelson Diagnostics announces £1.98 million financing
- Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia in $1 Billion Oncology Investment Alliance
- Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly
- Technology Strategy Board awards Accutronics £100,000 for medical battery
- Patent Published for Lumora’s Novel Sample Preparation Technology
- PolyTherics and TUBE Pharma collaborate to develop novel cytotoxic payloads for antibody drug conjugates (ADCs)
- Innovative new Blade Inspection System launched
- Probe Scientific signs new licensing deal with Menarini
- Zinwave in-building wireless system interfaces with managed access systems deployed by the military and correctional institutions
- Catapult makes key appointment
- Biofortuna raises £1.3m of investment for growth in its freeze-dried molecular diagnostics business and service provision
- Crystallon instals 2000th Cryostream
- PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
- Sky will use a joint NICE-Silver Lining workforce optimisation solution to more effectively manage its multi-site, multi-skill, contact centre environment.
- Lumora Signs Supply Agreement with Promega for Ultra-Glo Luciferase, to be used in Lumora’s BART Molecular Diagnostics Technology
- Sight and Sound celebrate winning the Midlands Venture Capital backed team of the year award at the gala dinner
- Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman
- Monica Healthcare developing new generation products
- Michelson Diagnostics wins Regulatory Approval for VivoSight OCT Scanner in Australia
- Lumora agrees licence and development program for Veterinary applications with Biogal Galed Labs
- RTS ‘gears up’ to grab larger slice of renewable energy sector
- British Gas leads £7m investment in telecoms and data centre efficiency company 4energy
- Catapult makes further investment into Kick Sport
- Probe Scientific signs a non-exclusive licence with Menarini Diagnostics
- Oxford BioTherapeutics and Boehringer Ingelheim enter collaboration to discover novel antibody targets in cancer
- Lumora to partner with FIND to develop new, high-throughput Malaria molecular diagnostic test for use in the developing world
- Sight and Sound Technology win BVCA Award
- Biofilm Shortlisted for BVCA Awards
- Lumora raises £700,000 to accelerate commercial development
- Catapult announces further investment in nanoTherics
- Portfolio Company Silver Lining Solutions Partners with NICE to Enhance Employee Performance and Training
- Catapult Exits Whelan Refining
- Sight & Sound Technology short-listed for BVCA awards
- BWB builds up with DKS Consulting deal
- Accutronics wins Award for Innovation in Products and Processes at the Manufacturing Excellence Awards
- Oxford BioTherapeutics Sign Major Strategic Collaboration with Menarini Group
- Catapult Venture Managers' portfolio company, Haemostatix, receives Wellcome Trust backing to take lead product into clinical development
- Catapult Venture Managers' Portfolio Company, Hangar Seven, Acquires Doco London
- Comply Serve wins BANEDANMARK Signalling Project Contract
- Cyclops & Telmap Announce Global Live Service Content Partnership
- Michelson Diagnostics appoints Xavier Yon as Non Executive Director
- Catapult secures a successful exit from Blackstar Amplification through secondary sale of its stake to Foresight Group
- Accutronics Wins Small Business of the Year Award
- Top of the Spotters - Cyclops Speedwatch wins Auto Express Recommended Award
- Hangar Seven Takes Off With Catapult Investment
- Catapult Deliver Knockout Investment Into Kick Sport
- Catapult Mops Up With Investment Into ACS
- Lumora Attracts Second Stage Funding
- Catapult and Mercia Invest into 'Cutting Edge' Intelligent Orthopaedics
- Monica Healthcare gains FDA clearance for groundbreaking wireless fetal monitor
- The Co-Operative and Catapult Finance MBO of World Leading Oxford Cryosystems
- Catapult and Mercia Invest in Staffordshire Based nanoTherics
- Catapult Invests in Mobile Video Delivery Technology
- Catapult Invests in Fast Growing Renewable Energy Sector
- Contact
